# Nanomotion-based Resistell AST to Determine the Antibiotic Susceptibility of Gram-negative Bacteria Causing Bacteremia and/or Sepsis

> **NCT05002413** · — · COMPLETED · sponsor: **Resistell AG** · enrollment: 300 (actual)

## Conditions studied

- Bacteremia Sepsis

## Interventions

- **DIAGNOSTIC_TEST:** Resistell AST

## Key facts

- **NCT ID:** NCT05002413
- **Lead sponsor:** Resistell AG
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-18
- **Primary completion:** 2024-02-19
- **Final completion:** 2024-02-19
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2024-04-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05002413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05002413, "Nanomotion-based Resistell AST to Determine the Antibiotic Susceptibility of Gram-negative Bacteria Causing Bacteremia and/or Sepsis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05002413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*